Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11963359 | 1.00 | CYP2C9 (0.32) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL20354560 | 0.75 | — | — | |
| SCHEMBL20444318 | 0.73 | — | — | |
| SCHEMBL13677601 | 0.73 | — | — | |
| SCHEMBL13677600 | 0.73 | — | — | |
| SCHEMBL21278247 | 0.71 | — | — | |
| SCHEMBL12892128 | 0.70 | CYP2C9 (0.35) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL2757138 | 0.67 | — | — | |
| SCHEMBL21169203 | 0.65 | — | — | |
| SCHEMBL19034907 | 0.64 | DPP4 (0.30) | CYP2C9TSHRCYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-02-07 | — | — | US | disclosed |
| US-10106500-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170247325-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-08-31 | — | — | US | disclosed |
| US-9675583-B2 | Selective androgen receptor modulators (SARMS) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160038461-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-02-11 | — | — | US | disclosed |
| US-9139520-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140350065-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-11-27 | — | — | US | disclosed |
| US-8748633-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130184206-A1 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2222636-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARM INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8354446-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2489656-A1 | Selective androgen receptor modulators (sarms) and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2012-01-05 | — | — | US | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
| EP-2222636-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | Ligand Pharmaceuticals Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009082437-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184206-A1 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1557/4885TSHR 765/4885CYP2C19 1502/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | CYP2C9 1076/4885TSHR 606/4885CYP2C19 1021/4885 |
| US-20170247325-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-10106500-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | CYP2C9 1076/4885TSHR 606/4885CYP2C19 1021/4885 |
| US-20160038461-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-20190040006-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-20140350065-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1958/4885TSHR 763/4885CYP2C19 1991/4885 |
| US-10730831-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | CYP2C9 1076/4885TSHR 606/4885CYP2C19 1021/4885 |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP2C9 1557/4885TSHR 765/4885CYP2C19 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.